Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

The gap between tech leaders' AI optimism and public backlash over data centers is widening, with two-thirds of Americans opposing local data centers.

Small card businesses are losing thousands to mail-order theft, forcing new packaging, insurance, and delivery strategies.

The AI boom's biggest political problem: voters love the product, hate the infrastructure. Here's how Trump and both parties are navigating the backlash.

With a fractured opposition making a stable majority impossible, Tokyo's ruling party is quietly reviving its old tie-up - and that changes every boardroom's political risk calculus.

OpenAI's CEO pushes back on water consumption fears, citing office-building parity and almond comparisons, even as public opposition mounts.

New polling shows overwhelming public opposition to government access to encrypted messages, even as the UK pursues secret orders against tech firms.